We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanoarray Senses and Distinguishes Multiple Diseases

By LabMedica International staff writers
Posted on 12 Jan 2017
Exhaled breath contains nitrogen, carbon dioxide and oxygen, as well as a small amount of more than 100 other volatile chemical components and the relative amounts of these substances vary depending on the state of a person's health.

An artificially intelligent nanoarray based on molecularly modified gold nanoparticles and a random network of single-walled carbon nanotubes for noninvasive diagnosis and classification of a number of diseases from exhaled breath has been developed.

An international team of scientists led by those at the Technion−Israel Institute of Technology, collected breath samples between January 2011 and June 2014 from 14 departments in nine clinical centers worldwide and were subjected to meta-analysis. More...
The team developed an array of nanoscale sensors to detect the individual components in thousands of breath samples from patients who were either healthy or had one of 17 different diseases, such as kidney cancer or Parkinson's disease.

To transfer exhaled volatile organic compounds (VOCs) the samples underwent thermal desorption (at 250 °C) in a TD20 auto sampler thermal desorption system before they were temporarily stored in a stainless steel VICI sample loop at 150 °C. One of the two breath samples from each subject was analyzed using gas chromatography–mass spectrometry (GC-MS) to determine the chemical nature and composition of the exhaled breath. For this analysis, the Shimadzu GCMS-QP2010 was used combined with their thermal desorption system.

The performance of this artificially intelligent nanoarray was clinically assessed on breath samples collected from 1,404 subjects having one of 17 different disease conditions included in the study or having no evidence of any disease (healthy controls). Blind experiments showed that 86% accuracy could be achieved with the artificially intelligent nanoarray, allowing both detection and discrimination between the different disease conditions examined. Analysis of the artificially intelligent nanoarray also showed that each disease has its own unique breathprint, and that the presence of one disease would not screen out others.

The diagnosis and classification power of the nanoarray was also validated by an independent analytical technique, gas chromatography linked with mass spectrometry. This analysis found that 13 exhaled chemical species are associated with certain diseases, and the composition of this assembly of volatile organic compounds differs from one disease to another. The study was published on December 21, 2016, in the journal ACS Nano.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automatic CLIA Analyzer
Shine i6000
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings indicate that measuring Lp(a) may help identify individuals at increased lifetime risk of atherosclerosis beyond conventional cardiovascular risk factors. (Image Credit: Adobe Stock)

Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis

Lipoprotein(a), or Lp(a), is a genetically determined blood lipid and an important risk factor for cardiovascular disease. Its relationship to long-term carotid atherosclerosis has remained unclear, particularly... Read more

Molecular Diagnostics

view channel
Image: The study was carried out by Start4All, a partnership led by Liverpool School of Tropical Medicine (LSTM) with the Stop TB Partnership and research partners in seven countries with a high TB burden (Photo courtesy of Liverpool School of Tropical Medicine)

Pooled Sputum Testing Offers Lower-Cost Molecular Diagnosis for Tuberculosis

Tuberculosis remains a major diagnostic challenge, with many cases going undetected and untreated. Limited access to rapid molecular diagnostic tests can delay diagnosis and allow transmission to continue... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.